bioAffinity Technologies, Inc. (BIAF) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

bioAffinity Technologies, Inc.

BIAF

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

19M

Medical - Diagnostics & Research

Next Earning date - 12 Nov 2024

19M

Medical - Diagnostics & Research

Next Earning date - 12 Nov 2024

1.40USD

0.11 ( 8.53%)

Relative Strenght

87

Volume Buzz

85%

Earning Acce

Yes

Dist 52w H.

61%

Quote Panel

Updated October 26, 2024

1W -2.78 % 1M -32.04 % 3M -46.77 % 1Y 3.70 %

Key Metrics

Market Cap
18.89M
Shares Outstanding
13.49M
Share in Float
7.45M
Dividende
0

Earning Date
12 Nov 2024
Price Target
1.4
Average Volume
141982
Beta
2.934

Range
1.15-3.62
Industry
Medical - Diagnostics & Research
Website
https://www.bioaffinitytech.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

2.58x

P/S Ratio

4.64x

P/B Ratio

0.1

Debt/Equity

-119.4%

Net Margin

$-0.9

EPS

How BIAF compares to sector?

P/E Ratio

Relative Strength

BIAF

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$11M

379%

2025-Revenue

$0.60

-216%

2025-EPS

$2M

219%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-1.10
vs -0.55

Q4.22

N/A

-0.20
vs -2.04

Q1.23

N/A

-0.18
vs -0.54

Q2.23

N/A

-0.20
vs -0.18

Q3.23

N/A

-0.26
vs -1.10

Q4.23

N/A

-0.26
vs -0.20

Q1.24

N/A

-0.21
vs -0.18

Q2.24

N/A

-0.19
vs -0.20

Q3.24

N/A

-0.15
vs -0.26

Q4.24

N/A

-0.14
vs -0.26

Sales Growth

YoY

Current

Estimates

Q3.22

NA

1.1K vs NA

Q4.22

NA

2.3K vs NA

Q1.23

NA

921 vs NA

Q2.23

+1411%

19.7K vs 1.3K

Q3.23

+25855%

298.5K vs 1.1K

Q4.23

+94246%

2.2M vs 2.3K

Q1.24

+261180%

2.4M vs 921

Q2.24

+12047%

2.4M vs 19.7K

Q3.24

+751%

2.5M vs 298.5K

Q4.24

+20%

2.6M vs 2.2M

Return on Equity

QoQ

Q3.22

-39%

-0.39
vs 0.03

Q4.22

-15%

-0.15
vs -0.39

Q1.23

-16%

-0.16
vs -0.15

Q2.23

-21%

-0.21
vs -0.16

Q3.23

-33%

-0.33
vs -0.21

Q4.23

-49%

-0.49
vs -0.33

Q1.24

-37%

-0.37
vs -0.49

Q2.24

-61%

-0.61
vs -0.37

Institutionnal Ownership

Earnings Growth

Latest News

BIAF

businesswire.com

8 hours ago

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

BIAF

businesswire.com

10 hours ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

BIAF

prnewswire.com

11 hours ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

BIAF

businesswire.com

12 hours ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

BIAF

prnewswire.com

14 hours ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

BIAF

prnewswire.com

14 hours ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

New Feature Coming Soon, Stay Tuned!

Shape

Shape